MedTrace Logo

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

NCT03746912 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-04-15

No results posted yet for this study

Summary

An expanded access program (EAP):

* Allows doctors to give medicine to patients,
* Before it is approved by health authorities.

This EAP is for:

* Quizartinib
* Patients with FLT3-ITD mutated AML,
* AML that has come back, or
* Is resistant to other therapies.

A participant will receive quizartinib if:

* The doctor submits a request,
* The participant is eligible, and
* The country allows the EAP.

Conditions

  • Acute Myeloid Leukemia With Gene Mutations

Interventions

DRUG

Quizartinib Dihydrochloride

Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746912 on ClinicalTrials.gov